Announcements Trials
Browse Landscape

Phase

Phase 2 4

Status

Terminated 2Active not recruiting 2

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 2Gastrointestinal 1

Conditions

Prostatic Neoplasms 1Lymphatic Metastasis 1Ependymoma 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1

Interventions

Cyclophosphamide 908Carboplatin 785Paclitaxel 739pembrolizumab 738Cisplatin 707Bevacizumab 705Gemcitabine 619Docetaxel 578Rituximab 548Radiotherapy 539Dexamethasone 510Nivolumab 485Doxorubicin 444Fluorouracil 392Capecitabine 376Etoposide 357Pemetrexed 334Cytarabine 334Oxaliplatin 333Lenalidomide 327Prednisone 326fludarabine phosphate 315Erlotinib Hydrochloride 314Trastuzumab 300Leucovorin 299fludarabine 296Vincristine 287Filgrastim 284Bortezomib 284Cetuximab 274

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Has results × Metastasectomy × Clear all
NCT02125786 2026-02-24

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

St. Jude Children's Research Hospital

Phase 2 Active not recruiting
68 enrolled 11 charts

Ependymoma

NCT02738606 2026-02-17

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

M.D. Anderson Cancer Center

Phase 2 Terminated
29 enrolled 8 charts
Gastrointestinal

Colorectal Neoplasms

NCT03796767 2026-01-28

SOAR

University of Utah

Phase 2 Active not recruiting
20 enrolled 26 charts
Genitourinary

Lymphatic Metastasis, Prostatic Neoplasms

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

University of California, San Francisco

Phase 2 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡